MétaCan
Menu
Back to cohort
Record W2883968393 · doi:10.18632/oncotarget.25697

Patient derived renal cell carcinoma xenografts exhibit distinct sensitivity patterns in response to antiangiogenic therapy and constitute a suitable tool for biomarker development

2018· article· en· W2883968393 on OpenAlexaffabout
Julia Schüler, Kerstin Klingner, Daniel Bug, Caren Zoeller, Armin Maier, Meng Dong, Kerstin Willecke, Anne-Lise Peille, Eva Steiner, Manuel Landesfeind, John A. Copland, Gabrielle M. Siegers, Axel Haferkamp, Katharina Böehm, Igor Tsaur, Meike Schneider

Bibliographic record

VenueOncotarget · 2018
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicAdvanced Glycation End Products research
Canadian institutionsUniversity of Alberta
FundersDeutsche Krebshilfe
KeywordsSunitinibMedicineBiomarkerAxitinibBevacizumabTemsirolimusPazopanibSorafenibRenal cell carcinomaHMGB1OncologyInternal medicineTargeted therapyCancer researchCancerHepatocellular carcinomaChemotherapyDiscovery and development of mTOR inhibitorsPI3K/AKT/mTOR pathwayBiologySignal transduction

Abstract

fetched live from OpenAlex

// Julia Schueler 1 , Kerstin Klingner 1 , Daniel Bug 3 , Caren Zoeller 7 , Armin Maier 1 , Meng Dong 8 , Kerstin Willecke 8 , Anne-Lise Peille 1 , Eva Steiner 4 , Manuel Landesfeind 1 , John A. Copland 2 , Gabrielle M. Siegers 6 , Axel Haferkamp 5 , Katharina Boehm 5 , Igor Tsaur 5 and Meike Schneider 5 1 Charles River Discovery Research Services Germany GmbH, Freiburg, Germany 2 Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA 3 LfB – Lehrstuhl für Bildverarbeitung, RWTH Aachen University, Aachen, Germany 4 Department of Urology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany 5 Department of Urology, Medical Center Johannes Gutenberg University, Mainz, Germany 6 Department of Experimental Oncology, University of Alberta, 5-142W Katz Group Centre, Edmonton, Canada 7 Department of Radiation Oncology, University Hospital of Würzburg, Würzburg, Germany 8 Dr. Margarete Fischer-Bosch - Institut für Klinische Pharmakologie, Stuttgart, Germany Correspondence to: Meike Schneider, email: meikeschneider310@gmail.com Keywords: HMGB1; renal cell carcinoma; damage associated molecular pattern; bevacizumab; VEGF Received: November 11, 2017     Accepted: June 12, 2018     Published: July 24, 2018 ABSTRACT Systemic treatment is necessary for one third of patients with renal cell carcinoma. No valid biomarker is currently available to tailor personalized therapy. In this study we established a representative panel of patient derived xenograft (PDX) mouse models from patients with renal cell carcinomas and determined serum levels of high mobility group B1 (HMGB1) protein under treatment with sunitinib, pazopanib, sorafenib, axitinib, temsirolimus and bevacizumab. Serum HMGB1 levels were significantly higher in a subset of the PDX collection, which exhibited slower tumor growth during subsequent passages than tumors with low HMGB1 serum levels. Pre-treatment PDX serum HMGB1 levels also correlated with response to systemic treatment: PDX models with high HMGB1 levels predicted response to bevacizumab. Taken together, we provide for the first time evidence that the damage associated molecular pattern biomarker HMGB1 can predict response to systemic treatment with bevacizumab. Our data support the future evaluation of HMGB1 as a predictive biomarker for bevacizumab sensitivity in patients with renal cell carcinoma.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.258
Threshold uncertainty score0.593

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.021
GPT teacher head0.284
Teacher spread0.263 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations9
Published2018
Admission routes2
Has abstractyes

Explore more

Same venueOncotargetSame topicAdvanced Glycation End Products researchFrench-language works237,207